This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Genotyping of Cytomegalovirus From Patients in Israel

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2006 by Sheba Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: September 26, 2005
Last updated: August 17, 2006
Last verified: January 2006
The researchers select 100 cytomegalovirus (CMV) DNA samples from patients diagnosed with CMV infection. Patients include bone marrow transplant patients, pregnant women and newborns. The researchers determine viral load by real-time polymerase chain reaction (PCR). They amplify CMV-gB sequences by PCR and type by sequencing and restriction fragment length polymorphism (RFLP). The researchers obtain clinical data from patients' records. They examine association between patients' clinical status and CMV-gB genotype and viral load.

Cytomegalovirus Infections

Study Type: Observational
Study Design: Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Official Title: Cytomegalovirus Glycoprotein B Genotypes in Israeli Patients: Relationship Between CMV Genotype, Clinical and Demographic Factors

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Estimated Enrollment: 100
Study Start Date: September 2005
Detailed Description:

The study aims at finding association between CMV viral load and viral glycoprotein B genotype and the clinical status of patients suffering from CMV infection. Bone marrow transplant patients are at increased risk of developing severe CMV disease and are routinely followed for viral load. Fetuses are also at high risk for developing severe malformations and neurological defects following maternal primary infection during pregnancy. Therefore amniotic fluid from women diagnosed with CMV infection is examined for CMV presence. Newborns having congenital defects are tested for CMV excretion.

There is not yet any confirmed marker for assessment of the potential severity of the viral infection and for prognosis. Therefore we shall attempt to find association between the viral load and genotype and the clinical status.

CMV DNA samples prepared at the Central Virology Laboratory from clinical specimens obtained from patients for diagnostic purposes will be coded and then subjected to viral load analysis using real-time PCR. The gB genotype will be determined by either of two methods described in the literature: (a) PCR and RFLP (b) PCR and sequencing.

Relevant clinical data will be retrieved from the patients clinical records and saved as coded information to match the samples. Bone marrow transplant patients will be followed for prolonged periods covering repeated viral reactivation events. Clinical records from mothers and newborns will be matched when present. Otherwise maternal and newborn samples will be kept as is.

Statistical analysis will be performed to try and find association between the clinical status of patients, the viral load and the viral genotype.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CMV DNA sample from a transplant patient with CMV disease.
  • CMV DNA from amniotic fluid of women with CMV infection
  • CMV DNA from urine of newborns with congenital defects compatible with CMV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00228202

Contact: Ella Mendelson, PhD 972-3-530-2421
Contact: Naty Keller, MD/PhD 972-3-530-2304

Central Virology Laboratory, Chaim Sheba Medical Center Tel-Hashomer Recruiting
Ramat Gan, Israel, 52621
Contact: Ella Mendelson, PhD    972-3-530-2421   
Contact: Zehava Grossman, PhD    972-3-530-2458   
Principal Investigator: Ella Mendelson, PhD         
Sub-Investigator: Musa Hindiyeh, PhD         
Sponsors and Collaborators
Sheba Medical Center
Study Director: Naty Keller, MD/PhD Sheba Medical Center
  More Information Identifier: NCT00228202     History of Changes
Other Study ID Numbers: SHEBA-05-3867-NK-CTIL
Sara Orzi MSc thesis
Study First Received: September 26, 2005
Last Updated: August 17, 2006

Keywords provided by Sheba Medical Center:
amniotic fluid
bone marrow
viral load
glycoprotein B
real-time PCR
CMV disease
Congenital CMV infection

Additional relevant MeSH terms:
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases processed this record on September 20, 2017